New study highlights significant potential medicare savings through use of castle biosciences' decisiondx®-scc test to guide adjuvant radiation therapy decisions in patients with cutaneous squamous cell carcinoma

Friendswood, texas--(business wire)---- $cstl #cstl--new study finds using castle's decisiondx-scc test to guide art decisions for scc patients could result in substantial medicare healthcare savings.

CSTL Ratings Summary

CSTL Quant Ranking